Temat: "Pancreatic Neoplasms" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Pancreatic Cancer: A Review of Current Treatment and Novel Therapies.
Autorzy:: Kolbeinsson HM; Spectrum Health General Surgery Residency, Grand Rapids, Michigan, USA.; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.
Chandana S; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.; Cancer and Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan, USA.
Wright GP; Spectrum Health General Surgery Residency, Grand Rapids, Michigan, USA.; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.; Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan, USA.
Chung M; Spectrum Health General Surgery Residency, Grand Rapids, Michigan, USA.; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.; Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan, USA.; Pokaż więcej
Źródło:: Journal of investigative surgery : the official journal of the Academy of Surgical Research [J Invest Surg] 2023 Dec 31; Vol. 36 (1), pp. 2129884. Date of Electronic Publication: 2022 Oct 03.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Pancreatic Neoplasms*/therapy
Pancreatic Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Humans ; United States ; Combined Modality Therapy ; Neoadjuvant Therapy ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: In silico identification and biological evaluation of a selective MAP4K4 inhibitor against pancreatic cancer.
Autorzy:: Chang CD; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Chao MW; School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.; Institute of Biopharmaceutical Sciences, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
Lee HY; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.
Liu YT; School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
Tu HJ; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Lien ST; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Lin TE; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Sung TY; Biomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
Yen SC; Warshel Institute for Computational Biology, The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong, People's Republic of China.
Huang SH; Graphen Inc, New York, NY, USA.
Hsu KC; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan.; Cancer Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Pan SL; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.; TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan.; Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.; TMU Research Center for Drug Discovery, Taipei Medical University, Taipei, Taiwan.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2166039.
Typ publikacji:: Journal Article
MeSH Terms:: Pancreatic Neoplasms*/enzymology
Protein Serine-Threonine Kinases*/antagonists & inhibitors
Protein Kinase Inhibitors*/chemistry
Protein Kinase Inhibitors*/pharmacology
Antineoplastic Agents*/chemistry
Antineoplastic Agents*/pharmacology
Humans ; Cell Line, Tumor ; Gemcitabine/chemistry ; Gemcitabine/pharmacology ; Intracellular Signaling Peptides and Proteins ; Computer Simulation ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors.
Autorzy:: Yang B; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Quan Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Zhao W; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Ji Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Yang X; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Li J; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Li Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Liu X; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Wang Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Li Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.; Pokaż więcej
Źródło:: Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2023 Dec; Vol. 38 (1), pp. 2169282.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents*/pharmacology
Pancreatic Neoplasms*/drug therapy
Humans ; Mice ; Animals ; Cell Line, Tumor ; Cell Cycle Checkpoints ; Protein Kinase Inhibitors/pharmacology ; Cell Proliferation ; Apoptosis ; Pyrimidines/pharmacology ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Treatment with anticancer drugs for advanced pancreatic cancer: a systematic review.
Autorzy:: Salazar J; Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
Bracchiglione J; Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.; CIBER Epidemiología Y Salud Pública (CIBERESP), Barcelona, Spain.; Interdisciplinary Centre for Health Studies CIESAL, Universidad de Valparaíso, Viña del Mar, Chile.
Savall-Esteve O; Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain.
Antequera A; International Health Department, ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
Bottaro-Parra D; Unitat de Cures Pal·Liatives de L'Institut d'Oncologia de La Catalunya Sud, Hospital Universitari Sant Joan de Reus, Tarragona, Spain.
Gutiérrez-Valencia M; Unit of Innovation and Organization, Navarre Health Service, Pamplona, Spain.; Navarre Institute for Health Research (IdiSNA), Pamplona, Spain.
Martínez-Peralta S; Unitat Cures Pal·Liatives, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
Pericay C; Servicio de Oncología Médica, Fundació Assistencial Mûtua Terrassa, Terrassa - Barcelona, Spain.
Tibau A; Oncology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.; Institut d'Investigació Biomèdica Sant Pau, Barcelona, Spain.; Universitat Autònoma Barcelona, Barcelona, Spain.
Bonfill X; Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain. .; CIBER Epidemiología Y Salud Pública (CIBERESP), Barcelona, Spain. .; Universitat Autònoma Barcelona, Barcelona, Spain. .; Pokaż więcej
Corporate Authors:: Appropriateness of Systemic Oncological Treatments for Advanced Cancer (ASTAC) Research Group
Źródło:: BMC cancer [BMC Cancer] 2023 Aug 12; Vol. 23 (1), pp. 748. Date of Electronic Publication: 2023 Aug 12.
Typ publikacji:: Systematic Review; Journal Article
MeSH Terms:: Antineoplastic Agents*/adverse effects
Pancreatic Neoplasms*/drug therapy
Humans ; Quality of Life ; Immunotherapy/methods ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Antibody drug conjugates: hitting the mark in pancreatic cancer?
Autorzy:: Wittwer NL; Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, University of South Australia, Adelaide, SA, 5000, Australia. .; Adelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia. .
Brown MP; Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, University of South Australia, Adelaide, SA, 5000, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, SA, 5000, Australia.
Liapis V; Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, University of South Australia, Adelaide, SA, 5000, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.
Staudacher AH; Translational Oncology Laboratory, Centre for Cancer Biology, SA Pathology, University of South Australia, Adelaide, SA, 5000, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, SA, 5000, Australia.; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Oct 25; Vol. 42 (1), pp. 280. Date of Electronic Publication: 2023 Oct 25.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Immunoconjugates*/pharmacology
Immunoconjugates*/therapeutic use
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Pancreatic Neoplasms*/drug therapy
Humans ; Antibodies, Monoclonal/therapeutic use ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: FAM3 family genes are associated with prognostic value of human cancer: a pan-cancer analysis.
Autorzy:: Dong QT; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China.; The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Ma DD; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China.
Gong Q; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China.
Lin ZY; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China.; The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Li ZH; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China.
Ye JX; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China.
Qin CH; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China.
Jin WD; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China.; The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
Zhang JX; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China. mai_.
Zhang ZY; Department of General Surgery, General Hospital of Central Theater Command, Wuhan, 430070, Hubei, China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Sep 13; Vol. 13 (1), pp. 15144. Date of Electronic Publication: 2023 Sep 13.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Pancreatic Neoplasms*/genetics
Liver Neoplasms*
Antineoplastic Agents*
Humans ; Prognosis ; Tumor Microenvironment/genetics ; Neoplasm Proteins ; Cytokines ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Momordicae Semen inhibits migration and induces apoptotic cell death by regulating c-Myc and CNOT2 in human pancreatic cancer cells.
Autorzy:: Jee W; College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-Ro, Dongdaemun-Gu, Seoul, 02447, Korea.; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, Korea.
Ko HM; College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-Ro, Dongdaemun-Gu, Seoul, 02447, Korea.; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, Korea.
Park DI; College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-Ro, Dongdaemun-Gu, Seoul, 02447, Korea.; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, Korea.
Park YR; College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-Ro, Dongdaemun-Gu, Seoul, 02447, Korea.; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, Korea.
Park SM; College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-Ro, Dongdaemun-Gu, Seoul, 02447, Korea.; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, Korea.
Kim H; Department of Korean Rehabilitation Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Korea.
Na YC; Western Seoul Center, Korea Basic Science Institute, 150 Bugahyeon-Ro, Seodaemun-Gu, Seoul, 03759, Republic of Korea.
Jung JH; College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-Ro, Dongdaemun-Gu, Seoul, 02447, Korea.; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, Korea.
Jang HJ; College of Korean Medicine, Kyung Hee University, 26, Kyungheedae-Ro, Dongdaemun-Gu, Seoul, 02447, Korea. .; Department of Science in Korean Medicine, Graduate School, Kyung Hee University, Seoul, 02447, Korea. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Aug 07; Vol. 13 (1), pp. 12800. Date of Electronic Publication: 2023 Aug 07.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents*/pharmacology
Pancreatic Neoplasms*/drug therapy
Humans ; Cell Line, Tumor ; Seeds ; Apoptosis ; Plant Extracts/chemistry ; Cell Proliferation ; Repressor Proteins/pharmacology ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Activated NAD+ biosynthesis pathway induces olaparib resistance in BRCA1 knockout pancreatic cancer cells.
Autorzy:: Sasaki Y; Department of Pharmacology, Faculty of Dentistry, Osaka Dental University, Hirakata, Osaka, Japan.; Department of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto, Nagasaki, Japan.
Inouchi T; Department of Pharmacology, Faculty of Dentistry, Osaka Dental University, Hirakata, Osaka, Japan.
Nakatsuka R; Department of Pharmacology, Faculty of Dentistry, Osaka Dental University, Hirakata, Osaka, Japan.
Inoue A; Department of Pharmacology, Faculty of Dentistry, Osaka Dental University, Hirakata, Osaka, Japan.
Masutani M; Department of Molecular and Genomic Biomedicine, Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Sakamoto, Nagasaki, Japan.
Nozaki T; Department of Pharmacology, Faculty of Dentistry, Osaka Dental University, Hirakata, Osaka, Japan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2024 Apr 16; Vol. 19 (4), pp. e0302130. Date of Electronic Publication: 2024 Apr 16 (Print Publication: 2024).
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents*/pharmacology
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Piperazines*
Humans ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; NAD ; Cell Line, Tumor ; Phthalazines/pharmacology ; BRCA1 Protein

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Nuclear MAST4 Suppresses FOXO3 through Interaction with AKT3 and Induces Chemoresistance in Pancreatic Ductal Carcinoma.
Autorzy:: Fujiwara-Tani R; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Sasaki T; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Bhawal UK; Research Institute of Oral Science, Nihon University School of Dentistry at Matsudo, Matsudo 271-8587, Chiba, Japan.
Mori S; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Ogata R; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Sasaki R; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Ikemoto A; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Kishi S; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.; Pathology Laboratory, Research Institute, Tokushukai Nozaki Hospital, 2-10-50 Tanigawa, Daito 574-0074, Osaka, Japan.
Fujii K; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Ohmori H; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Sho M; Department of Surgery, Nara Medical University, Kashihara 634-8522, Nara, Japan.
Kuniyasu H; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Apr 05; Vol. 25 (7). Date of Electronic Publication: 2024 Apr 05.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Antineoplastic Agents*
Humans ; Drug Resistance, Neoplasm/genetics ; Microtubules ; Gemcitabine ; Forkhead Box Protein O3/genetics ; Proto-Oncogene Proteins c-akt ; Microtubule-Associated Proteins ; Protein Serine-Threonine Kinases

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: The Effect of 4-(Dimethylamino)phenyl-5-oxopyrrolidines on Breast and Pancreatic Cancer Cell Colony Formation, Migration, and Growth of Tumor Spheroids.
Autorzy:: Kairytė K; Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų Rd. 19, LT-50254 Kaunas, Lithuania.
Vaickelionienė R; Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų Rd. 19, LT-50254 Kaunas, Lithuania.
Grybaitė B; Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų Rd. 19, LT-50254 Kaunas, Lithuania.
Anusevičius K; Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų Rd. 19, LT-50254 Kaunas, Lithuania.
Mickevičius V; Department of Organic Chemistry, Kaunas University of Technology, Radvilėnų Rd. 19, LT-50254 Kaunas, Lithuania.
Petrikaitė V; Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio Al. 7, LT-10257 Vilnius, Lithuania.; Faculty of Medicine, Lithuanian University of Health Sciences, A. Mickevičiaus 9, LT-44307 Kaunas, Lithuania.; Laboratory of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, Sukilėlių Pr. 13, LT-50162 Kaunas, Lithuania.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 02; Vol. 25 (3). Date of Electronic Publication: 2024 Feb 02.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents*/therapeutic use
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Triple Negative Breast Neoplasms*/drug therapy
Humans ; Structure-Activity Relationship ; Cell Proliferation ; Hydrazones/pharmacology ; Pyrrolidinones/pharmacology ; Cell Line, Tumor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition.
Autorzy:: Deben C; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium. .
Boullosa LF; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.
Fortes FR; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.
De La Hoz EC; Industrial Vision Lab, University of Antwerp, Wilrijk, Belgium.
Le Compte M; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.
Seghers S; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.
Peeters M; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.
Vanlanduit S; Industrial Vision Lab, University of Antwerp, Wilrijk, Belgium.
Lin A; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Plasma Lab for Applications in Sustainability and Medicine ANTwerp (PLASMANT), University of Antwerp, Wilrijk, Belgium.
Dijkstra KK; Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Oncode Institute, Utrecht, The Netherlands.
Van Schil P; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium.
Hendriks JMH; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Edegem, Belgium.
Prenen H; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Oncology, Multidisciplinary Oncological Center Antwerp, Antwerp University Hospital, Antwerp, Belgium.
Roeyen G; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Department of Hepatobiliary Transplantation and Endocrine Surgery, University Hospital Antwerp (UZA), Edegem, Belgium.
Lardon F; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.
Smits E; Center for Oncological Research (CORE), Integrated Personalized & Precision Oncology Network (IPPON), University of Antwerp, Wilrijk, Belgium.; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.; Pokaż więcej
Źródło:: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 Mar 22; Vol. 43 (1), pp. 88. Date of Electronic Publication: 2024 Mar 22.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/genetics
Pancreatic Neoplasms*/pathology
Carcinoma, Pancreatic Ductal*/drug therapy
Adenocarcinoma*/drug therapy
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Carbonic Anhydrases*
Humans ; Auranofin/pharmacology ; Auranofin/therapeutic use ; Proto-Oncogene Proteins c-akt/metabolism ; Drug Repositioning ; Lung/pathology ; Biomarkers ; Organoids/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: The Conjugates of Indolo[2,3- b ]quinoline as Anti-Pancreatic Cancer Agents: Design, Synthesis, Molecular Docking and Biological Evaluations.
Autorzy:: Cybulski M; Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, Łukasiewicz Research Network-Industrial Chemistry Institute, 01-793 Warsaw, Poland.
Sidoryk K; Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, Łukasiewicz Research Network-Industrial Chemistry Institute, 01-793 Warsaw, Poland.
Zaremba-Czogalla M; Department of Lipids and Liposomes, Faculty of Biotechnology, University of Wroclaw, 50-383 Wroclaw, Poland.
Trzaskowski B; Chemical and Biological Systems Simulation Lab, Center of New Technologies, University of Warsaw, 02-097 Warsaw, Poland.
Kubiszewski M; Pharmaceutical Analysis Laboratory, Łukasiewicz Research Network-Industrial Chemistry Institute, 01-793 Warsaw, Poland.
Tobiasz J; Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, Łukasiewicz Research Network-Industrial Chemistry Institute, 01-793 Warsaw, Poland.
Jaromin A; Department of Lipids and Liposomes, Faculty of Biotechnology, University of Wroclaw, 50-383 Wroclaw, Poland.
Michalak O; Pharmacy, Cosmetic Chemistry and Biotechnology Research Group, Łukasiewicz Research Network-Industrial Chemistry Institute, 01-793 Warsaw, Poland.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 22; Vol. 25 (5). Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:: Journal Article
MeSH Terms:: Pancreatic Neoplasms*
Quinolines*
Antineoplastic Agents*
Humans ; Molecular Docking Simulation ; Pancreatic Hormones ; Coumaric Acids ; Multienzyme Complexes ; DNA ; Structure-Activity Relationship ; Molecular Structure ; Cell Line, Tumor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development.
Autorzy:: Ranđelović I; KINETO Lab Ltd., 1037 Budapest, Hungary.
Nyíri K; Laboratory of Genome Metabolism and Repair, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, Hungarian Research Network, 1117 Budapest, Hungary.; Department of Applied Biotechnology and Food Science, BME Budapest University of Technology and Economics, 1111 Budapest, Hungary.
Koppány G; Laboratory of Genome Metabolism and Repair, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, Hungarian Research Network, 1117 Budapest, Hungary.; Department of Applied Biotechnology and Food Science, BME Budapest University of Technology and Economics, 1111 Budapest, Hungary.
Baranyi M; KINETO Lab Ltd., 1037 Budapest, Hungary.; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 1091 Budapest, Hungary.
Tóvári J; Department of Experimental Pharmacology and the National Tumor Biology Laboratory, National Institute of Oncology, 1122 Budapest, Hungary.
Kigyós A; KINETO Lab Ltd., 1037 Budapest, Hungary.
Tímár J; Department of Pathology, Forensic and Insurance Medicine, Semmelweis University, 1091 Budapest, Hungary.
Vértessy BG; Laboratory of Genome Metabolism and Repair, Institute of Molecular Life Sciences, Research Centre for Natural Sciences, Hungarian Research Network, 1117 Budapest, Hungary.; Department of Applied Biotechnology and Food Science, BME Budapest University of Technology and Economics, 1111 Budapest, Hungary.
Grolmusz V; Department of Computer Science, Mathematical Institute, Eötvös Loránd University, 1117 Budapest, Hungary.; Uratim Ltd., 1118 Budapest, Hungary.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2024 Feb 22; Vol. 25 (5). Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:: Journal Article
MeSH Terms:: Pancreatic Neoplasms*/pathology
Adenocarcinoma*/genetics
Antineoplastic Agents*
Humans ; Proto-Oncogene Proteins p21(ras)/metabolism ; Drug Development

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: High glucose-upregulated PD-L1 expression through RAS signaling-driven downregulation of PTRH1 leads to suppression of T cell cytotoxic function in tumor environment.
Autorzy:: Gao C; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Chen J; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Bai J; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Zhang H; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Tao Y; Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Wu S; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Li H; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Wu H; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.; Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Shen Q; Louisiana State University Health Sciences Center, New Orleans, LA, 70112, USA.
Yin T; Department of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. .; Sino-German Laboratory of Personalized Medicine for Pancreatic Cancer, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. .; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2023 Jul 11; Vol. 21 (1), pp. 461. Date of Electronic Publication: 2023 Jul 11.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents*
B7-H1 Antigen*/genetics
Diabetes Mellitus, Experimental*
Pancreatic Neoplasms*/genetics
Animals ; Mice ; CD8-Positive T-Lymphocytes ; Down-Regulation/genetics ; Mice, Inbred C57BL ; Signal Transduction ; Tumor Microenvironment ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Lovastatin Treatment Inducing Apoptosis in Human Pancreatic Cancer Cells by Inhibiting Cholesterol Rafts in Plasma Membrane and Mitochondria.
Autorzy:: Gyoten M; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Luo Y; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.; Jiangsu Province Key Laboratory of Neuroregeneration, Nantong University, 19 Qixiu Road, Nantong 226001, China.
Fujiwara-Tani R; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Mori S; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Ogata R; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.
Kishi S; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.; Research Institute, Nozaki Tokushukai Hospital, 2-10-50 Tanigawa, Daito 574-0074, Osaka, Japan.
Kuniyasu H; Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Nov 27; Vol. 24 (23). Date of Electronic Publication: 2023 Nov 27.
Typ publikacji:: Journal Article
MeSH Terms:: Hydroxymethylglutaryl-CoA Reductase Inhibitors*/pharmacology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/metabolism
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/metabolism
Carcinoma, Pancreatic Ductal*/metabolism
Humans ; bcl-2-Associated X Protein/metabolism ; Lovastatin/pharmacology ; Proto-Oncogene Proteins c-akt/metabolism ; Apoptosis ; Cell Membrane/metabolism ; Gemcitabine ; Membrane Microdomains/metabolism ; ErbB Receptors/metabolism ; Mitochondria/metabolism ; Cholesterol/metabolism ; Cell Line, Tumor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor.
Autorzy:: Ingle K; Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States of America.
LaComb JF; Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States of America.
Graves LM; Department of Pharmacology, School of Medicine, the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Baines AT; Department of Pharmacology, School of Medicine, the University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.; Department of Biological & Biomedical Sciences, College of Health & Sciences, North Carolina Central University, Durham, North Carolina, United States of America.
Bialkowska AB; Department of Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, New York, United States of America.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2023 Nov 09; Vol. 18 (11), pp. e0294065. Date of Electronic Publication: 2023 Nov 09 (Print Publication: 2023).
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: Pancreatic Neoplasms*/pathology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Carcinoma, Pancreatic Ductal*/pathology
Humans ; Phosphatidylinositol 3-Kinases/metabolism ; Growth Inhibitors/pharmacology ; Gemcitabine ; TOR Serine-Threonine Kinases ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use ; Phosphoinositide-3 Kinase Inhibitors/pharmacology ; Cell Proliferation ; Cell Line, Tumor

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Use of DNA-alkylating pyrrole-imidazole polyamides for anti-cancer drug sensitivity screening in pancreatic ductal adenocarcinoma.
Autorzy:: Tsujimoto A; Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.; Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Matsuo N; Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Lai X; Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.; Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.
Inoue T; Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Yoda H; Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Lin J; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Shinozaki Y; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Watanabe T; Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Koshikawa N; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.
Takatori A; Division of Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Chiba, Japan.
Nagase H; Graduate School of Medical and Pharmaceutical Sciences, Chiba University, Chiba, Japan.; Division of Cancer Genetics, Chiba Cancer Center Research Institute, Chiba, Japan.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2023 Mar; Vol. 12 (5), pp. 5821-5832. Date of Electronic Publication: 2022 Oct 19.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/pathology
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Animals ; Mice ; Humans ; Nylons/pharmacology ; Nylons/metabolism ; Proto-Oncogene Proteins p21(ras)/genetics ; Proto-Oncogene Proteins p21(ras)/metabolism ; DNA/therapeutic use ; Imidazoles/pharmacology ; Imidazoles/therapeutic use ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Anticancer Activity of Sunitinib Analogues in Human Pancreatic Cancer Cell Cultures under Normoxia and Hypoxia.
Autorzy:: Skaraitė I; Laboratory of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50162 Kaunas, Lithuania.
Maccioni E; Department of Life and Environmental Sciences, University of Cagliari, Via Ospedale 72, 09124 Cagliari, Italy.
Petrikaitė V; Laboratory of Drug Targets Histopathology, Institute of Cardiology, Lithuanian University of Health Sciences, Sukileliu pr. 13, LT-50162 Kaunas, Lithuania.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Mar 12; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 12.
Typ publikacji:: Journal Article
MeSH Terms:: Pancreatic Neoplasms*/pathology
Adenocarcinoma*/drug therapy
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Sunitinib/pharmacology ; Sunitinib/therapeutic use ; Cell Culture Techniques ; Hypoxia/drug therapy ; Cell Line, Tumor ; Cell Proliferation ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Irreversible Electroporation in Pancreatic Cancer-An Evolving Experimental and Clinical Method.
Autorzy:: Gajewska-Naryniecka A; Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.
Szwedowicz U; Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.
Łapińska Z; Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.
Rudno-Rudzińska J; 2nd Department of General Surgery and Surgical Oncology, Medical University Hospital, Borowska 213, 50-556 Wroclaw, Poland.
Kielan W; 2nd Department of General Surgery and Surgical Oncology, Medical University Hospital, Borowska 213, 50-556 Wroclaw, Poland.
Kulbacka J; Department of Molecular and Cellular Biology, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211A, 50-556 Wroclaw, Poland.; Department of Immunology, State Research Institute Centre for Innovative Medicine, Santariškių 5, 08410 Vilnius, Lithuania.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Feb 23; Vol. 24 (5). Date of Electronic Publication: 2023 Feb 23.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Pancreatic Neoplasms*/pathology
Antineoplastic Agents*
Humans ; Combined Modality Therapy ; Electroporation/methods ; Treatment Outcome ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Unravelling the enigma of siRNA and aptamer mediated therapies against pancreatic cancer.
Autorzy:: Liu Z; Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, Shenyang, China.
Parveen N; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Rehman U; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Aziz A; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Sheikh A; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India.
Abourehab MAS; Department of Pharmaceutics, College of Pharmacy, Umm Al-Qura University, Makkah, 21955, Saudi Arabia.
Guo W; Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, Shenyang, China.
Huang J; Department of Pancreatic-Biliary Surgery, The First Hospital of China Medical University, Shenyang, China.
Wang Z; Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, 155N. Nanjing Street, Shenyang, 110001, Liaoning, China. .; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, 110122, Liaoning, China. .; Institute of Health Sciences, China Medical University, Shenyang, 110122, Liaoning, China. .
Kesharwani P; Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India. .; Center for Transdisciplinary Research, Department Of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science, Chennai, India. .; Pokaż więcej
Źródło:: Molecular cancer [Mol Cancer] 2023 Jan 12; Vol. 22 (1), pp. 8. Date of Electronic Publication: 2023 Jan 12.
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents*/therapeutic use
Aptamers, Nucleotide*/genetics
Aptamers, Nucleotide*/therapeutic use
Aptamers, Nucleotide*/chemistry
Pancreatic Neoplasms*/therapy
Pancreatic Neoplasms*/drug therapy
Humans ; RNA, Small Interfering/genetics ; Quality of Life ; Neoplasm Recurrence, Local/drug therapy ; Pancreatic Neoplasms

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Pancreatic Neoplasms"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język